Search

Your search keyword '"Liming, Huang"' showing total 2 results
Start Over Author "Liming, Huang" Publication Type Magazines
2 results on '"Liming, Huang"'

1. Facile fabrication of boron-doped titanium carbide for efficient electrocatalytic nitrogen reductionElectronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d3cy00726j

Author

Leiming, Tao, Kui, Pang, Wen, Qin, Liming, Huang, Linhai, Duan, Guanhua, Zhu, Qiuye, Li, and Changlin, Yu

Abstract

Electrochemical nitrogen fixation is a promising strategy to achieve sustainable ammonia (NH3) synthesis. However, the major challenge lies in simultaneously achieving high NH3production rates and faradaic efficiency (FE). A well-designed catalyst with high nitrogen reduction reaction (NRR) performance is urgently needed. Herein, we report a novel boron-doped titanium carbide (Ti3C2–B) material prepared by doping B into intercalated carbide titanium (Ti3C2) MXenes. The NH3yield of Ti3C2–B catalysts was examined using two detection techniques: ultraviolet-visible spectroscopy and ion chromatography. The synthesized electrocatalyst exhibited an NH3yield of 39.64 ± 1.4 μg h−1mgcat.−1at −0.55 V and an FE of 11.89% ± 0.3% at −0.45 V vs.reversible hydrogen electrode (RHE), outperforming most reported NRR catalysts. Density functional theory (DFT) calculations suggest that B doping of Ti3C2reduces the free energy obstacle for the rate-determining step *NNH2→ *NNH3, enhances the suppression of the hydrogen evolution reaction (HER), and improves NRR capabilities. B doping of 2D MXene nanosheets offers a promising avenue for developing highly efficient N2electrocatalysts in the future.

Published
2023
Full Text
View/download PDF

2. Gender differences in lipid goal attainment among Chinese patients with coronary heart disease: insights from the DYSlipidemia International Study of China

Author

Yu, Bilian, Zhao, Shuiping, Hu, Dayi, Ambegaonakr, Baishaili M., Investigators, on Behalf of the DYSIS-China Study, Investigators, on Behalf of the DYSIS-China Study, Jia Er, Bu Ai, Guiwen, Cao, Buxing, Chen, Hong, Chen, Jin, Chen, Jing, Chen, Liefeng, Chen, Min, Chen, Qiong, Chen, Shaoliang, Chen, Tielong, Chen, Xiaofei, Chen, Xiaohong, Chen, You, Chen, Guoli, Cheng, Mei, Cheng, Hongliang, Cong, Qin, Cui, Shiwei, Cui, Yong, Cui, Shudong, Dai, Henghua, Dai, Xiaomei, Deng, Yirong, Di, Xiaoyan, Ding, Birong, Dong, Yumei, Dong, Yugang, Dong, Ping, Du, Lei, Duan, Limei, Fan, Ningyuan, Fang, Lixia, Fei, Lie, Feng, Jun, Ge, GeWeihong, Hongmin, Guo, Minxia, Guo, Qinghua, Han, Fengchang, He, Dayi, Hu, Lingzhi, Hu, Xueqiang, Hu, Yaojun, Hu, Yiming, Hu, Zhiping, Hu, Fei, Hua, Qi, Hua, Dejia, Huang, Gewen, Huang, Hongman, Huang, Liming, Huang, Qiong, Huang, Ruowen, Huang, Taifu, Huang, Bin, Jiang, Kai, Jiao, Hui, Jin, Huigen, Jin, Jinsong, Kuang, Bao, Li, Chengjiang, Li, Hongjuan, Li, Jun(Xinjiang), Li, Jun(Jiangsu), Li, Nanfang, Li, Qifu, Li, Qiang, Li, Xin, Li, Xueyou, Li, Yanbing, Li, Yanping, Li, Yansheng, Li, Yong, Li, Yuling, Li, Zhanquan, Li, Zhengfang, Li, Li, Liang, Yongxue, Liang, Zerong, Liang, Yuhua, Liao, Fan, Liu, Hong, Liu, Hui, Liu, Minling, Liu, Qiang, Liu, Qingsong, Liu, Shaokui, Liu, Weidong, Liu, Xueping, Liu, Xinjian, Lu, Benyan, Luo, Shaonian, Luo, Suxin, Luo, Hong, Lv, LvYun, Aiqun, Ma, Jianhua, Ma, Qiang, Ma, Yan, Ma, Changsheng, Ma, Yide, Miao, Yiming, Mu, NieXiaoli, NiuXiaoyuan, Hongtao, Pan, Mingkang, Pan, Qiaoqing, Peng, Huifen, Qian, Qiumin, Qu, Lijie, Qu, Liqun, Ren, Jingshan, Shao, Qiang, Se, Jing, Huang, Xiuyun, Shen, Yongquan, Shi, Liangyi, Si, Zhi, Song, Zhiyuan, Song, Yufeng, Sun, Chunyan, Tan, TengXiaochun, Haoming, Tian, Wenhua, Tian, Qinwei, Tong, TuQiuyun, Keying, Wang, Aihong, Wang, Chaohui, Wang, Chunning, Wang, Dezhao, Wang, Guixia, Wang, Hanqiao, Wang, Jianan, Wang, Jianjun, Wang, Lan, Wang, Xiaoming, Wang, Yaping, Wang, Yangwei, Wang, Yongjun, Wang, Meifang, Wei, Yidong, Wei, Hongyun, Wu, Chun, Wu, Dongmei, Wu, Jiang, Wu, Jun, Wu, Xiaolin, Wu, Zonggui, Wu, XiGuangxia, Yi, Xiang, Qian, Xiao, Xiaoping, Xing, Yulong, Xing, Anding, Xu, XueYuanming, Chuanzhu, Yan, Tao, Yan, Xiaowei, Yan, Gangyi, Yang, Jian, Yang, Wangpingm, Yang, Xiaosu, Yang, Xinchun, Yang, Yifang, Yang, Yu, Yang, Mingyu, Yao, Min, Ye, Ping, Ye, Bo, Yu, Jiangyi, Yu, Jinming, Yu, Yan, Yu, Ling, Zeng, Longyi, Zeng, Xiaoyun, Zeng, Baorong, Zhang, Bei, Zhang, Chaoxin, Zhang, Xuelian, Zhang, Dadong, Zhang, Dongping, Zhang, Fuchun, Zhang, Hong, Zhang, Huifang, Zhang, Liping, Zhang, Liyang, Zhang, Rufu, Zhang, Saidan, Zhang, Weijuan, Zhang, Dong, Zhao, Gang, Zhao, Shuiping, Zhao, Xiuxin, Zhao, Qiangsun, Zheng, Yang, Zheng, Xiaohui, Zhou, Yali, Zhou, Yujie, Zhou, Yi, Zhu, Yulan, Zhu, and Xiangping, Zou

Abstract

Despite great advances in lipid-lowering therapy, the gender-based disparities in lipid goal success among Chinese coronary heart disease (CHD) patients receiving lipid-lowering treatment remained uncharacterized. Furthermore, little is known about potential causes for this gender imbalance. This cross-sectional trial included 25 697 patients treated with lipid-lowering agents from 122 centres between April 2012 and October 2012; data for 9420 participants with CHD were analysed in the present study; all underwent clinical examination and had their latest fasting lipid profiles while on lipid-lowering therapy recorded. Logistic regression was used to explore possible factors associated with gender disparity in goal attainment rates, and to what extent each factor contributes. Of 9420 CHD patients (42.5% women) evaluated, women had a significantly lower overall low-density lipoprotein cholesterol (LDL-C) success rate than men (46.2 vs. 62.7%, P < 0.0001). Among CHD patients with diabetes, only 31.5% of women and 46.4% of men (P < 0.0001) attained the optional LDL-C target of <80 mg/dL. More than half (54.0%) of female patients failed to attain their non-high-density lipoprotein cholesterol (HDL-C) goal. Approximately 7.5, 8.8, 7.5, and 6.8% of gender disparity in LDL-C goal attainment rate was attributable to the gender difference in use of an anti-diabetic, anti-hypertensive, anti-platelet treatment, and the dosage of statin treatment, respectively. Although great improvements have been made over the past decade, there is still a preventive gap in high-risk and very high-risk CHD patients regarding LDL-C and non-HDL-C levels and that this gap is apparently greater in women.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results